FDA Accepts BLA for Garzulys (Insulin Aspart-FSAN) by Emerge Bioscience
The FDA has accepted the Biologics License Application for Garzulys, an insulin aspart formulation.
Asset / Drug
Drug and asset intelligence for Garzulys with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.